IODINATED FATTY ACID ESTERS CONTAINING A MINIMUM OF 50 PERCENT OF MONOIODOSTEARIC ACID ESTERS OR DERIVATIVES IN THE FORM OF A SOFT CAPSULE OR A GEL CAPSULE, OF USE DURING A NUCLEAR ACCIDENT

摘要

Iodinated fatty acid esters containing a minimum of 50 percent of monoiodostearic acid esters such as ethyl esters of fatty acids originating from rapeseed oil, or derivatives, of pharmaceutical purity, which are completely iodinated, no longer have double bonds, and are stable, for preparing an organism-protecting product, of medicament quality, either in the pure state in a pharmaceutical form such as a soft capsule or a gel capsule, or in combination with excipients in a soft-capsule or gel-capsule form, for oral administration, which is of use during a nuclear accident, enabling a prolonged provision of an additional dose of iodine to the thyroid gland and in which the amount of iodine administrated follows the recommendations of the World Health Organization. Thus, the use of defined doses for oral administration, stable for 5 years or even 10 years at 25°C, either of a soft capsule containing 351 mg of Brassiodol corresponding to a concentration of 100 mg of ¹²⁷Ifor children over the age of 12 and adults, or of a soft capsule containing 175 mg of Brassiodol corresponding to a concentration of 50 mg of ¹²⁷Ifor children from 36 months to 12 years old, or of a soft capsule containing 88 mg of Brassiodol corresponding to a concentration of 25 mg of ¹²⁷I for infants from 1 to 36 months old, is recommended. These soft capsules of Brassiodol can be used by populations in regions where there is a relative deficiency in dietary iodine, allowing supplementary preventive coverage for the thyroid gland for 6 months.